Ardelyx Inc (ARDX)

NASDAQ
3.630
+0.110(+3.12%)
Pre Market
3.679
+0.048(+1.34%)
- Real-time Data
  • Volume:
    2,843,767
  • Day's Range:
    3.460 - 3.655
  • 52 wk Range:
    0.490 - 5.125

ARDX Overview

Prev. Close
3.52
Day's Range
3.46-3.655
Revenue
63.07M
Open
3.5
52 wk Range
0.49-5.125
EPS
-0.371
Volume
2,843,767
Market Cap
778.5M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
6,501,830
P/E Ratio
-8.88
Beta
1.17
1-Year Change
440.66%
Shares Outstanding
214,462,429
Next Earnings Date
10 Aug 2023
What is your sentiment on Ardelyx Inc?
or
Market is currently closed. Voting is open during market hours.

Ardelyx Inc Company Profile

Ardelyx Inc Company Profile

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Read More

Analyst Price Target

Average7.083 (+95.132% Upside)
High10.000
Low5.000
Price3.630
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralSell
Technical IndicatorsSellStrong BuyStrong BuyStrong SellStrong Buy
SummaryNeutralStrong BuyStrong BuySellNeutral
  • what on earth is shifting this stock went up double digits on Friday
    0
    • They have got permission to release a drug in 2022 which will have a huge impact on their bottom line
      0
  • -7
    0